| |
|
|
| Issue 200: October 12, 2007: |
 |
Issue 199: October 5, 2007: |
 |
| William C. Crawford
, Director of Industry Relations, Children's Hospital Informatics Program, on creating a market for personally-controlled health records.
|
|
|
 |
| Gokhan S. Hotamisligil, M.D., Ph.D.
, Chair, Department of Genetics and Complex Diseases, and J.S. Simmons Professor of Genetics & Metabolism, Harvard School of Public Health, on therapies at the interface of metabolic and inflammatory diseases. |
|
|
|
| Issue 198: September 28, 2007: |
|
Issue 197: September 21, 2007: |
 |
| Daniel J. Carlat, M.D.
, Assistant Clinical Professor of Psychiatry, Tufts University School of Medicine, and Editor-in-Chief, The Carlat Psychiatry Report, on industry sponsorship of continuing medical education.
|
|
|
 |
| Paul Burn, Ph.D.
, Senior Vice President of Research & Development, Juvenile Diabetes Research Foundation (JDRF), on JDRF's increased focus on translational and clinical research. |
|
|
|
| Issue 196: September 14, 2007: |
|
Issue 194: August 31, 2007: |
 |
| Sara Rosenbaum,
Chair, Department of Health Policy, School of Public Health and Health Services, George Washington University Medical Center, on the SCHIP reauthorization bill.
|
|
|
 |
| Frank Burroughs
, President, Abigail Alliance for Better Access to Developmental Drugs, on his organization's push for ACCESS legislation.
|
|
|
|
| Issue 192: August 10, 2007: |
|
Issue 189: July 20, 2007: |
|
|
| Pieter Muntendam M.D.
, President and CEO, and Robert N. McBurney, Ph.D., Senior Vice President, Research & Development, and Chief Scientific Officer, BG Medicine, on creating biomarkers as decision tools for molecular medicine.
|
|
|
 |
| J. Scott Tarrant
, VP of Business Development, Xceleron Inc., on prioritizing compounds with human PK data through microdosing studies.
|
|
|
|
| Issue 188: July 13, 2007: |
|
Issue 187: July 6, 2007: |
 |
| Barry J. Schindler,
Shareholder, Greenberg Traurig, LLP, on unresolved points of contention in the proposed patent reform bill.
|
|
|
 |
| Eileen Hilton, M.D.
, President and CEO, Biomedical Research Alliance of New York (BRANY), on BRANY's one-stop service for multi-center clinical trials. |
|
|
|
| Issue 186: June 29, 2007: |
|
Issue 182: June 29, 2007: |
 |
| Naomi Aronson, Ph.D.
, Executive Director, Blue Cross and Blue Shield Association (BCBSA) Technology Evaluation Center (TEC), on technology assessments and comparative effectiveness reviews.
|
|
|
 |
| Michael Milburn, Ph.D.
, Chief Scientific Officer, Metabolon, Inc., on using metabolomics in biomarker discovery and compound profiling. |
|
|
|
| Issue 179: May 11, 2007: |
|
Issue 178: May 4, 2007: |
 |
| Stuart W. Peltz, Ph.D.
, President and CEO, PTC Therapeutics, on his company's approach of using small molecules to regulate protein synthesis.
|
|
|
 |
| Bruce W. MacLennan,
Partner, Herrick Feinstein LLP, on negotiating licensing deals with biotech companies. |
|
|
|
| Issue 176: April 20, 2007: |
|
Issue 175: April 13, 2007: |
 |
| Daniel B. Ravicher
, President and Executive Director, Public Patent Foundation, on challenging bad patents to serve the public interest.
|
|
|
 |
| Jacques E. Rossouw, M.D.
, Chief of Women's Health Initiative Branch, National Heart, Lung, and Blood Institute, NIH, on refining treatment recommendations for hormone therapy. |
|
|
|
| Issue 174: March 30, 2007: |
|
Issue 172: March 16, 2007: |
 |
| Wayne Koberstein
, Consultant, on trends and developments among some of the key companies within the pharmaceutical industry.
|
|
|
 |
| William A. Sarraille
, Partner, Sidley Austin LLP, on the potential impact of CMS's proposed rules regarding Average Manufacturer Price (AMP) in Medicaid |
|
|
|
| Issue 171: March 9, 2007: |
|
Issue 169: February 23, 2007: |
 |
| Mark Kessel
, Co-Founder and Managing Director, Symphony Capital, on Symphony Capital's partnership approach to financing the development of early clinical-stage compounds.
|
|
|
 |
| William L. Warren
, Partner, Sutherland Asbill & Brennan LLP, on Representative Waxman's proposed bill on follow-on biologics.
|
|
|
|
| Issue 167: February 9, 2007: |
|
Issue 164 and 165: January 19 and 26, 2007: |
 |
| Lynn E. Eccleston
, Attorney, McGuire Woods LLP, on the ramifications of the Supreme Court's decision on declaratory judgments in MedImmune v. Genentech.
|
|
|
 |
| Shin-Ichiro Imai, M.D., Ph.D.
Assistant Professor, Molecular Biology and Pharmacology, Washington University School of Medicine, on research into Sir2 and longevity. |
|
|
|
| Issue 161: December 22, 2006: |
|
Issue 160: December 15, 2006: |
 |
| Kenneth A. Getz,
Senior Research Fellow, Tufts Center for the Study of Drug Development, on factors affecting speed and efficiency in clinical development. |
|
|
 |
| Louis A. Tartaglia, Ph.D., Senior Vice President and General Manager of Drug Repositioning and Selection, Gene Logic, on Gene Logic's drug repositioning business. |
|
|
|
| Issue 159: December 8, 2006: |
|
Issue 156: November 10, 2006: |
 |
| Gary P. Pisano, Professor, Harvard Business School, on his new book on the biotechnology industry, Science Business. |
|
|
 |
| Richard P. Burgoon, Jr., CEO, Aeolus Pharmaceuticals, Inc., on catalytic antioxidants and Aeolus' corporate strategy. |
|
|
|
| Issue 155: November 3, 2006: |
|
Issue 153: October 20, 2006: |
 |
| Marc Fisher, MD,
Professor of Neurology, University of Massachusetts Medical School, on new approaches for clinical development of stroke therapies. |
|
|
 |
| Eric Button, President and Managing Director, The BioMarker Group, on integrating biomarkers into drug development programs. |
|
|
|
| Issue 152: October 13, 2006: |
|
Issue 151: October 6, 2006: |
 |
| Alan Goldhammer,
Associate Vice President Regulatory Affairs, Pharmaceutical
Research and Manufacturers of America, on PhRMA's views
of the Institute of Medicine's recommendations to improve
drug safety. |
|
|
 |
| Arthur M.
Krieg, M.D., Senior Vice President, Research and
Development, and Chief Scientific Officer, Coley Pharmaceutical
Group, on Coley's development of CpG oligonucleotide
immunotherapeutics. |
|
|
|
| Issue 150: September 29, 2006: |
|
Issue 149: September 22, 2006: |
 |
| Brian P. Murphy,
Partner, Morgan, Lewis & Bockius LLP, on unresolved issues
in Hatch-Waxman settlement agreements.
|
|
|
|
|
| Mihael H.
Polymeropoulos, M.D., CEO, and Chip Clark, Chief
Business Officer, Vanda Pharmaceuticals, on Vanda's
genomics-based approach to product differentiation in the
market for CNS treatments. |
|
|
|
| Issue 148: September 15, 2006: |
|
Issue 147: September 8, 2006: |
|
| Gokhan S.
Hotamisligil, M.D., Ph.D., Chair, Department of Genetics
and Complex Diseases, Harvard School of Public Health, on
chemical chaperones that suppress ER stress as potential treatments
for diabetes. |
|
|
 |
| Fumihiko Urano,
M.D., Assistant Professor, University of Massachusetts
Medical School, on the role of IRE1 in insulin biosynthesis
in response to ER stress. |
|
|
|
| Issue 145: August 25, 2006: |
|
Issue 144: August 11, 2006: |
|
| Bruce E.
Schneider, Executive Vice President and Chief of
Operations, Wyeth Research, on Wyeth’s adoption of a
“learn and confirm” approach to clinical development.
|
|
|
 |
| Duane Thurman,
Director, Prescription Drug Program, Washington State Health
Care Authority, on the state’s preferred drug list and
efforts to promote evidence-based, cost-effective prescribing
behavior. |
|
|
|
| Issue 143: August 4, 2006: |
|
Issue 141: July 21, 2006: |
|
| Craig Atwood,
Assistant Professor, Department of Medicine, University of
Wisconsin, on the Reproductive-Cell Cycle Theory of Aging.
|
|
|
 |
Hiromi Yoshikawa,
Chairman and CEO, Otsuka America Pharmaceutical, Inc., on
the expansion of Otsuka's pharmaceutical business in the US.
|
|
|
|
| Issue 140: July 14, 2006: |
|
Issue 139: July 7, 2006: |
 |
| Daniel L.
Weiner, Senior Vice President, Software Products,
Pharsight Corporation, on Pharsight's CRADA with the FDA and
the infrastructure required for modeling and simulation in
clinical development. |
|
|
 |
Garo H. Armen,
Chairman and CEO, Antigenics Inc., on Oncophage, an experimental
cancer vaccine using heat shock proteins.
|
|
|
|
| Issue 138: June 30, 2006: |
|
Issue 136: June 16, 2006: |
 |
| Donald A.
Berry, Chairman, Department of Biostatistics, The
University of Texas MD Anderson Cancer Center, on the use
of Bayesian statistical methods in clinical development. |
|
|
 |
| John E. McDonough,
Executive Director, Health Care For All, on new legislation
designed to reduce the number of people without health insurance
in Massachusetts. |
|
|
|
| Issue 135: June 9, 2006: |
|
Issue 134: June 2, 2006: |
 |
| Robert J.
Feeney, Jr., President & CEO, MedVantx, on his
company's Sample Centers that dispense free generic drug samples. |
|
|
 |
| Dr. Anthony
Hayward, Director, Division of Clinical Research
Resources, National Center for Research Resources, NIH, on
a new Roadmap initiative to promote clinical research. |
|
|
|
| Issue 133: May 26, 2006: |
|
Issue 132: May 19 , 2006: |
 |
| Dr. Steve
E. Phurrough, Director, Coverage & Analysis Group,
CMS, on National Coverage Determinations for Part B Drugs
in Medicare. |
|
|
 |
Dr. Randall
S. Stafford, Assistant Professor of Medicine, Stanford
Prevention Research Center, on new research in off-label prescribing
patterns.
|
|
|
|
| Issue 131: May 12, 2006: |
|
Issue 129: April 21, 2006: |
 |
| Dr. Bruce
Silver, VP of Global Product Development Services
in Oncology, PRA International, on issues in cancer drug development. |
|
|
 |
| Dr. John T.
Santini, Jr., President, MicroCHIPS, Inc., on implantable
devices for drug delivery. |
|
|
|
| Issue 128: April 13, 2006: |
|
Issue 127: April 7, 2006: |
 |
| Diana Conmy,
Corporate Director of Market Insights at IMS Health,
on key developments for the pharmaceutical industry in 2005. |
|
|
 |
| Paul J. Hastings,
President and Chief Executive Officer of Oncomed, Inc., on
drugs to target cancer stem cells. |
|
|
|
| Issue 126: March 31, 2006: |
|
Issue 125: March 24, 2006: |
 |
| Dr. David
Sinclair, Associate Professor of Pathology at Harvard
Medical School, on the effects of SIR2 on the aging process. |
|
|
 |
| Dr. Abner
L. Notkins, Chief of Experimental Medicine for the
National Institute of Dental and Craniofacial Research at
the NIH, on the use of autoantibodies in predictive medicine. |
|
|
|
| Issue 124: March 17, 2006: |
|
Issue 123: March 10, 2006: |
 |
Michael Valentino,
Chief Consultant, PBM Strategic Healthcare Group, VA, on the
VAfs national formulary.
|
|
|
 |
| J.D. Kleinke,
Chairman & Executive Director, Omnimedix Institute, on
obstacles to the development of a viable HIT system. |
|
|
|
| Issue 121:February 24, 2006: |
|
Issue 120: February 17, 2006: |
 |
| Dr. Barry
Davis, Principal Investigator & Director, ALLHAT
Clinical Trials Center, on using the landmark ALLHAT results
to change prescribing behavior. |
|
|
 |
| Dr. Gerald
Reaven, Professor Emeritus (Active) of Medicine,
Stanford University, on insulin resistance syndrome. |
|
|
|
| Issue 117: January 27, 2006: |
|
Issue 116: January 20, 2006: |
 |
| Dr. Stanley
Ip, Project Leader, and Dr. Peter Bonis, Primary
Technical Expert, Tufts-New England Medical Center Evidence-based
Practice Center, on the comparative effectiveness of treatments
for gastroesophageal reflux disease. |
|
|
 |
| Dr. Timothy
Anderson, Senior Pharmaceutical Analyst, Prudential
Equity Group, LLC, on pharmaceutical patent expirations in
2006. |
|
|
|
| Issue 115:January 13, 2006: |
|
Issue 113: December 22, 2005: |
 |
| Dr. Kazuko
Nishikura, Professor, Gene Expression and Regulation
Program, The Wistar Institute, on her research into RNA editing
and microRNA. |
|
|
 |
| Dr. Alice
M. Rivlin, Senior Fellow in Economic Studies, The
Brookings Institution, on the fiscal sustainability of Medicare
spending. |
|
|
|
| Issue 112:December 16, 2005: |
|
Issue 110: December 2, 2005: |
 |
James M. Karis, President
& CEO, Entelos, Inc., on the role of in silico modeling
in drug development.
|
|
|
 |
| Jerry Avorn,
Professor of Medicine, Harvard Medical School, on academic
detailing and physician prescribing behavior. |
|
|
|
| Issue 109:November 18, 2005: |
|
Issue 108: November 11, 2005: |
 |
| Kenneth I. Kaitin, Director,
Tufts Center for the Study of Drug Development, on recent
drug output trends. |
|
|
 |
| Joan Alker,
Senior Researcher, Georgetown Health Policy Institute, on
Florida’s proposed changes to the state Medicaid program. |
|
|
|
| Issue 107:November 4, 2005: |
|
Issue 105: October 21, 2005: |
 |
Joshua Shinoff, Licensing
Officer, Office of Technology Licensing, on technology transfer
at UC Berkeley.
|
|
|
 |
| John A. Scarlett,
President and CEO, Tercica, on the company’s newly approved
treatment for short stature. |
|
|
|
| Issue 103:October 7, 2005: |
|
Issue 102: September 30, 2005: |
 |
| Jean R. Slutsky, Director,
Center for Outcomes and Evidence, on MMA provisions affecting
the Agency for Healthcare Research and Quality. |
|
|
 |
| Dara A. Corrigan,
Partner, Arnold & Porter, on new MMA priorities for the
Inspector General’s Office at HHS. |
|
|
|
| Issue 101:September 23, 2005: |
|
Issue 100: September 16, 2005: |
 |
Larry Gold, CEO & Chairman
of the Board, SomaLogic, Inc., on the uses of aptamer technology.
|
|
|
 |
Larry D. Sasich,
Staff Pharmacist, Public Citizen, on drug safety issues at
the FDA.
|
|
|
|
| Issue 99:September 9, 2005: |
|
Issue 98: September 2, 2005: |
 |
Mark Heesen,President, National
Venture Capital Association, on venture capital financing
trends in the biotech industry.
|
|
|
 |
| Dr. John A.
Gans,EVP and CEO, American Pharmacists Association,
on the role of pharmacists in improving drug safety. |
|
|
|
| Issue 97:August 26, 2005: |
|
Issue 96: August 12, 2005: |
 |
| David Largaespada,Associate
Professor, University of Minnesota Cancer Center, on a new
method of cancer-gene identification using the Sleeping Beauty
transposon. |
|
|
 |
| Makoto Nishimura,
President and CEO of Astellas Pharma US, Inc. on
Astellas’s strategy in U.S. market. |
|
|
|
| Issue 93:July 22, 2005: |
|
Issue 92: July 15, 2005: |
 |
| Sharon Anglin Treat, Executive
Director, National Legislative Association on Prescription
Drug Prices, on state-level initiatives to reduce prescription
drug prices.. |
|
|
 |
| Dr. Moriya
Tsuji, Associate Professor, Aaron Diamond AIDS Research
Center, Rockefeller University, on the discovery of new antigens
that bind to the CD1d receptor and activate NKT cells. |
|
|
|
| Issue 91:July 8, 2005: |
|
Issue 90: July 1, 2005: |
 |
| Larry McComber, VP Contract
and Program Services, Novation LLC, on GPO contracting for
prescription drugs. |
|
|
 |
Robert K. Passikoff, Founder
and President, Brand Keys, Inc., on DTC corporate and product
brand promotion.
|
|
|
|
| Issue 89:June 24, 2005: |
|
Issue 88: June 17, 2005: |
 |
| Jeffrey I.D. Lewis, Partner,
Patterson Belknap Webb & Tyler LLP, on the impact of the
Integra v. Merck decision on pharmaceutical research. |
|
|
 |
Shabbir Dahod, President
and CEO, SupplyScape Corporation, on developing an electronic
pedigree for the pharmaceutical supply chain.
|
|
|
|
| Issue 86:May 27, 2005: |
|
Issue 84: May 13, 2005: |
 |
| Michael Rosen, Chairman and
CEO, Immune Cell Therapy, Inc., on the life sciences hub in
the Midwest. |
|
|
 |
| Gary Zammit, President and
CEO, Clinilabs, Inc., on progress in developing treatments
for sleep disorders. |
|
|
|
| Issue 80:April 15, 2005: |
|
Issue 78: April 1, 2005 |
 |
| Frank M. Rapoport, Partner,
McKenna Long & Aldridge LLP, on the BioShield legislation
and the development of a biodefense industry. |
|
|
 |
| Steve Powell, Vice President
of Worldwide Sales, Phase Forward, Incorporated, on the use
of electronic data capture in clinical trials |
|
|
|
| Issue 77: March 25, 2005 |
|
Issue 76: March 18, 2005 |
 |
| Christopher Watts, Staff
Fellow, Center for Drug Evaluation and Research, FDA, on moving
to real time release with PAT. |
|
|
 |
| Daniel Devine, President
and CEO, Acceptys, Inc., on shifting from humanized to fully-human
monoclonal antibodies. |
|
|
|
| Issue 75: March 11, 2005 |
|
Issue 73: February 25, 2005 |
 |
| Alton C. Morgan, Chairman
and President, InNexus Biotechnology, Inc., on the development
of SuperAntibodies. |
|
|
 |
| Paul Cusenza, Vice President,
Alliance Management, Perlegen Sciences, Inc., on Perlegen’s
approach to high-density, whole genome SNP genotyping. |
|
|
|
| Issue 72: February 18, 2005 |
|
Issue 69: January 28, 2005 |
 |
| Derek Guyton, Principal,
Mercer Human Resources Consulting, on how employer-sponsored
retiree drug benefits are being affected by the MMA. |
|
|
 |
| Steven H. Sklar, Partner,
Leydig, Voit & Mayer, Ltd., on the Teva v. Pfizer decision
on declaratory judgment actions. |
|
|
|
| Issue 68: January 21, 2005 |
|
Issue 65: December 24, 2004 |
 |
| Vera Hassner Sharav, President,
Alliance for Human Research Protection, on how industry practices
in clinical trials have led to an erosion of public trust. |
|
|
 |
| Maxine Gowen, Managing Partner,
SR One, on the investment approach of a venture capital subsidiary
of a major pharmaceutical company. |
|
|
|
| Issue 63: December 10, 2004 |
|
Issue 61: November 19, 2004 |
 |
| John Santa, Medical Director
of the Center for Evidence-based Policy at Oregon Health and
Science University, on state initiatives to create a transparent
drug evaluation system for more cost-effective drug spending. |
|
|
 |
| J. David Haddox, Vice President,
Risk Management & Health Policy, Purdue Pharma, on a government-aided,
multifaceted approach to reduce the potential for abuse of
prescription pain treatments. |
|
|
|
| Issue 59: November 5, 2004 |
|
Issue 57: October 22, 2004 |
 |
| Mark Merritt, President
and CEO, Pharmaceutical Care Management Association, on the
role of pharmacy benefit managers in the Medicare prescription
drug benefit. |
|
|
 |
| Joseph S. McCracken, Vice
President, Business Development, Genentech, Inc., on Genentech's
approach to R&D and commercialization partnerships. |
|
|
|
| Issue 56: October 15, 2004 |
|
Issue 55: October 8, 2004 |
 |
| Kathleen Jaeger,
President and CEO, Generic Pharmaceutical Association, on
the scientific advancements facilitating regulatory evaluations
of biogenerics. |
|
|
 |
| Richard C. Aulatta, President,
R.C. Auletta and Co., on Merck's handling of the Vioxx recall. |
|
|
|
| Issue 52: September 17, 2004 |
|
Issue 51: September 10, 2004 |
 |
| Michael Krensavage,
Senior Vice President, Equity Research, Raymond James &
Associates, on Schering-Plough's turnaround strategy. |
|
|
 |
| Richard D. Kelly, Senior
Partner, Oblon, Spivak, McClelland, Maier & Neustadt,
P.C., on issues relating to authorized generics. |
|
|
|
| Issue 49: August 20, 2004 |
|
Issue 48: August 13, 2004 |
 |
| Jeffrey Aronin,
Founder, President and COO, Ovation Pharmaceuticals, on Ovation's
niche market business strategy. |
|
|
 |
| Nobuya Oka, Executive
Vice President, Takeda Pharmaceuticals North America, on Takeda's
strategy in the U.S. market. |
|
|
|
| Issue 47: August 6, 2004 |
|
Issue 45: July 23, 2004 |
 |
| Reeta Roy, Vice
President, Global Citizenship and Policy, Abbott Laboratories,
on Abbott's AIDS initiatives in developing countries. |
|
|
 |
| Kevin Outterson,
Associate Professor of Law, West Virginia University, on the
impact of the Australia-U.S. Free Trade Agreement on the market
for pharmaceuticals. |
|
|
|
| Issue 44: July 16, 2004 |
|
Issue 43: July 9, 2004 |
 |
| Vamsi K. Mootha,
M.D., Assistant Professor, Harvard Medical School, on the
team-science approach to biomedical research. |
|
|
|
| Michael M. Gottesman,
M.D., Deputy Director for Intramural Research, NIH, on intramural
research at the NIH. |
|
|
|
| Issue 42: July 2, 2004 |
|
Issue 41: June 25, 2004 |
 |
| Barry Greene, Chief Operating
Officer, Alnylam Pharmaceuticals, on RNAi therapeutics. |
|
|
 |
| Carl B. Feldbaum, President,
Biotechnology Industry Organization (BIO), on the development
of BIO and the biotech industry during his tenure. |
|
|
|
| Issue 40: June 18, 2004 |
|
Issue 37: May 28, 2004 |
 |
| Donald W. Moran, President,
The Moran Company, on New York Attorney General Eliot Spitzer's
fraud suit against GlaxoSmithKline. |
|
|
 |
| Frank F. Bilstein(Left),
Partner, and Razmic S. Gregorian, Jr.(Right),
Director, Simon-Kucher & Partners, on the impact of the
Medicare legislation on the environment for drug pricing in
the U.S. |
|
|
|
| Issue 36: May 21, 2004 |
|
Issue 35: May 14, 2004 |
 |
| Robert Monaghan(Left),
CEO, and Lawrence K. Cohen(Right), Vice Chairman,
Zyomyx Inc., on the use of protein chips in drug development. |
|
|
 |
Viren Mehta, Managing
Member, Mehta Partners LLC, on the merits of the Sanofi-Aventis
merger .
|
|
|
|
| Issue 34: May 7, 2004 |
|
Issue 32: April 23, 2004 |
 |
John Rother, Director
of Policy and Strategy, AARP, on the new Medicare drug discount
cards and legislative reform priorities for Medicare.
|
|
|
 |
Merrill Goozner,
Journalist and Project Director, Center for Science in the
Public Interest, on his new book, The $800 Million Pill.
|
|
|
|
| Issue 31: April 16, 2004 |
|
Issue 30: April 9, 2004 |
 |
Josef H. von Rickenbach,
Chairman and CEO, PAREXEL International, on current trends
in clinical development.
|
|
|
 |
Scott Gottlieb,
M.D.,Director of Medical Policy
Development, FDA, on Mark McClellan's tenure at the FDA. .
|
|
|
|
| Issue 29: April 2, 2004 |
|
Issue 28: March 26, 2004 |
 |
| Wayne Koberstein,
Contributing Editor, Contract Pharma, on globalization, consolidation,
and pharmaceutical market strategies. |
|
|
 |
| Barbara Yanni, Chief
Licensing Officer and Vice President, Merck & Co., Inc.,
on Merck’s in-licensing activities. |
|
|
|
| Issue 27: March 19, 2004 |
|
Issue 26: March 12, 2004 |
 |
| Steven Rauscher,
President and CEO, Genome Therapeutics, on the market launch
of Factive. |
|
|
 |
| Richard Trabert,
Public affairs consultant and faculty member at Boston College’s
Center for Corporate Citizenship, on social initiatives in
the pharmaceutical industry. |
|
|
|
| Issue 25: March 5, 2004 |
|
Issue 24: February 27, 2003 |
 |
| Lowell E. Schnipper, M.D.,
Harvard Medical School Professor and Chief of Hematology and
Oncology at Beth Israel Deaconess Medical Center, on synergies
between new and existing treatments in oncology. |
|
|
 |
| Soichi Matsuno,
Chairman, Eisai Inc., on Eisai’s strategy in the U.S.
market. |
|
|
|
| Issue 23: February 20, 2004 |
|
Issue 22: February 13, 2004 |
|
| Donald O. Beers,
Partner, Arnold & Porter, on polymorph patents. |
|
|
 |
| Ken Araki, Pharmaceutical
Industry Global Research Director, Nomura Securities International,
on the forces shaping change in the pharmaceutical industry. |
|
|
|
| Issue 21: February 6, 2004 |
|
Issue 19: January 23, 2004 |
 |
| Jean-Paul Modde,
Group President, Dendrite International, Inc., on new trends
in CRM in the pharmaceutical industry. |
|
|
 |
| Kevin Goodno, Commissioner,
Minnesota Department of Human Services, on Minnesota’s
initiatives toward prescription drug importation. |
|
|
|
| Issue 18: January 16,2004 |
|
Issue 15: December 12, 2003 |
 |
| Preston Henske,
Vice President, Bain & Company, on building a new business
model in the pharmaceutical industry. |
|
|
 |
| Kenneth S. Abramowitz,
Senior Advisor, The Carlyle Group, on the impact of Medicare
reforms on the HMO industry. |
|
|
|
| Issue 14: December 5, 2003 |
|
Issue 12: November 21, 2003 |
 |
| Anthony Robbins, M.D.,
Professor of Public Health, Tufts University School of Medicine,
on Medicare reform in historical perspective. |
|
|
 |
| Louis M. Solomon,
Partner, Proskauer Rose LLP, on Hatch-Waxman reforms. |
|
|
|
| Issue 11: November 14, 2003 |
|
Issue 10: November 7, 2003 |
 |
| Sharon Treat, Senate
Majority Leader, State of Maine, on Maine’s initiatives
to lower the cost of prescription drugs. |
|
|
 |
| Nick Naclerio, President,
ParAllele BioSciences, on pushing the boundaries of high-throughput
SNP genotyping. |
|
|
|
| Issue 9: October 31, 2003 |
|
Issue 7: October 17, 2003 |
 |
| Vibeke Strand, M.D.,
Adjunct Clinical Professor, Division of Immunology, Stanford
University, on new treatment therapies for rheumatiod arthritis. |
|
|
 |
| Christopher D. Hook,
Director for RFID Market Development & Deborah H. Murphy,
Life Sciences Market Development Manager, Zebra Technologies,
on technologies for pharmaceutical supply chains. |
|
|
|
| Issue 6: October 10, 2003 |
|
Issue 5: October 3, 2003 |
 |
| Brian G. Atwood,
Managing Director, Versant Ventures, on biotech venture capital
investing and market cycles. |
|
|
 |
|
| Glenn Rice, Vice
President for Biopharmaceutical Sciences, SRI International,
on bridging the gap from university research labs to clinical
trials. |
|
|
|
| Issue 4: September 26, 2003 |
|
Issue 3: September 19, 2003 |
 |
| Eric Lindsey, Vice
President for Business Development, PDI Inc., on salesforce
outsourcing. |
|
|
 |
| Jack Trout, President,
Trout & Partners, Ltd., on product positioning through
DTC advertising. |
|
|
|
| Issue 2: September 12, 2003 |
|
Issue 1: September 5, 2003 |
 |
| Tom Heyman, Executive
Vice President for Business Development, Johnson & Johnson,
on J&J’s in-licensing activities. |
|
|
 |
| Paula Campbell Evans,
Partner, Palmer & Dodge LLP, on the regulatory prospects
for generic biologics. |
|
|
